Medicina

Antecedentes: el suicidio y el intento de suicidio es un fenómeno poco estudiado en la población pediátrica y la información epidemiológica en este grupo de edad es poco confiable en nuestro país; por estas razones nace la importancia de este estudio. Métodos: se propone el desarrollo de una revisión ampliada de la literatura. Se realiza una búsqueda en las bases de datos del Ministerio de la Protección Social, OMS, OPS, Medline y LILACS. Se realizó un análisis crítico de la literatura de cada uno de los documentos adquiridos, evaluando la metodología propuesta, y los componentes expuestos en cada uno de los estudios. Resultados: el suicidio en la población infantil y adolescente es uno de los problemas que afronta nuestra sociedad de manera creciente y es un fenómeno multifactorial, que incluye factores causales biológicos, psicológicos y sociales. Conclusiones: después de la presente investigación se considera que el problema de suicidio en niños y adolescentes involucra múltiples factores que deben ser abordados cuanto antes desde diferentes niveles como la familia, la escuela y las autoridades de salud pública para hacer énfasis en los factores de riesgo que pueden impulsar a los menores a tomar esta decisión.

's first studies. Percutaneous coronary balloon angioplasty (PTCA) was first performed in 1982. Despite a progressively great interest and training of physicians in invasive cardiology there are still restrictions in its development. Most private institutions have modem facilities but their caseloads, ever increasing, are still limited because they take care of only 35% of the population. Public institutions are limited because offunding, and some are just developing PTCA. The situation has improved recently because of deals between the private and public systems. Experience with newer devices is even more limited. (J Interven Cardiol 1995; 8:29-32)

El Síndrom e de Sj ögren ( SS) es una enferm edad aut oinm une sist ém ica crónica con disfunción progresiva de glándulas lagr im ales y salivales( exocrinopat ia) caract erizado por hipert rofia glandular salival, xeroft alm ia ( querat oconj unt ivit is sicca) , xerost om ía, xerot raquea y sequedad m ucosa vaginal. Se asocia adem ás a m anifest aciones ext raglandulares com o poliart r it is no erosiva , fenóm eno de Raynaud. Adem ás puede exist ir infilt ración del t ej ido epit elial del pulm ón, r iñón e hígado, que aparecen t em prano en el curso de la enferm edad y t ienen un curso benigno.

IMPORTANCE Inflammation promotes cardiovascular disease and anti-inflammatory treatment reduces cardiovascular events in patients with chronic coronary syndrome. Chronic kidney disease (CKD) is a risk factor for cardiovascular disease. It is unclear how inflammation mediated by interleukin 6 (IL-6) in patients with CKD is linked to cardiovascular disease. OBJECTIVE To investigate associations between IL-6 and cardiovascular outcomes in patients with chronic coronary syndrome in association with kidney function. DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study included patients enrolled at 663 centers in 39 countries with chronic coronary syndrome who were included in the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy (STABILITY) trial. Patients were enrolled between December 2008 and April 2010 and were followed up for a median length of 3.7 years. Analysis in this substudy began September 2020. EXPOSURES Exposures were IL-6 and creatinine estimated glomerular filtration rates (eGFR), which were collected at baseline. Associations between continuous and categorical levels (<2.0 ng/L vs Ն2.0 ng/L) of IL-6 and cardiovascular outcomes were tested in association with eGFR cutoffs (normal eGFR level [Ն90 mL/min/1.73 m 2 ], mildly decreased eGFR level [60-90 mL/min/1.73 m 2 ], and moderately to severely decreased eGFR level [<60 mL/min/1.73 m 2 ]). MAIN OUTCOMES AND MEASURES Main outcome was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, and stroke. RESULTS This substudy of the STABILITY trial included 14 611 patients with available IL-6 levels at baseline. The median (interquartile range) age was 65 (59-71) years, and 2700 (18.5%) were female. During follow-up, MACE occurred in 1459 individuals (10.0%). Higher levels of IL-6 were in continuous models independently associated with risk of MACE (P < .001) in all CKD strata. Using predefined strata, elevated IL-6 level (Ն2.0 vs <2.0 ng/L) was associated with increased risk of MACE at normal kidney function (2.9% vs 1.9% events/y [hazard ratio, 1.35; 95% CI, 1.02-1.78]), mild CKD (3.3% vs 1.9% [hazard ratio, 1.57; 95% CI, 1.35-1.83]), and moderate to severe CKD (5.0% vs 2.9% [hazard ratio, 1.60; 95% CI, 1.28-1.99]). CONCLUSIONS AND RELEVANCE In patients with chronic coronary syndrome, elevated levels of IL-6 were associated with risk of MACE in all CKD strata. Thus, IL-6 and CKD stage may help when identifying patients with chronic coronary syndrome for anti-inflammatory treatment.